EBUS Biopsy Confidence: Lung Cancer Guideline Review
Summary of the Interview with Abhinav Agrawal, MD on Lung Biopsies & Biomarker testing
This interview with Dr. Abhinav Agrawal discusses a new clinical practice guideline from the AABIP and IASLC regarding lung biopsy techniques for diagnosis and biomarker testing in lung cancer. hear’s a breakdown of the key takeaways:
Key Issues Addressed:
Shifting landscape: Lung cancer diagnosis is evolving with increased screening and the need for biomarker testing to personalize treatment.
Comparing Biopsy Methods: The guideline compares EBUS-guided biopsy (endobronchial ultrasound) with CT-guided biopsy and mediastinoscopy.
Sample Adequacy: A central question is whether biopsies obtained through these methods provide enough tissue for extensive biomarker testing, especially with expanding gene panels.
Key Findings & Recommendations:
Robotic/Navigational Bronchoscopy: This technique is proving to be as diagnostically effective as CT-guided biopsy, and safer (lower risk of pneumothorax) for peripheral pulmonary nodules. It also yields sufficient tissue for biomarker testing.
EBUS-Guided Biopsy for Lymph nodes: EBUS is now the preferred first-line approach for mediastinal/hilar lymph node biopsy due to its safety (less invasive) and comparable diagnostic/biomarker yield to mediastinoscopy.
Mediastinoscopy’s Remaining role: mediastinoscopy is now reserved for specific situations:
Investigating false negatives after a negative EBUS result.
Staging small cell lung cancer to check for microscopic disease in the mediastinum (though this is becoming less common).
Biomarker Testing Adequacy: Bronchoscopic biopsies, notably when combined with techniques like cryobiopsy, can provide enough tissue for biomarker testing and inform personalized treatment plans. NGS (Next-Generation Sequencing) is becoming more effective with smaller samples.
Data Considerations: The guideline focused on data from the last 10 years to account for the availability of expanded gene panels for biomarker analysis.
Overall Message:
The trend is towards less invasive, bronchoscopic techniques (especially robotic/navigational bronchoscopy and EBUS) for both diagnosing lung cancer and obtaining adequate tissue for the increasingly crucial task of biomarker testing. These methods are proving to be safe and effective, allowing for more personalized treatment approaches.